Archive · 7 Nov 2025
Trump Administration Finalizes Deals to Lower Weight-Loss Drug Prices
The President has made deals with two big medicine companies, Eli Lilly and Novo Nordisk, that make popular weight-loss drugs.
These drugs, like Zepbound and Wegovy, can be very expensive, costing over $1,000 each month.
Now, these companies have agreed to sell them for much less.
For some people using Medicare, the cost could be as low as $50 each month.
Others who are overweight might pay around $245 a month for the injectable versions.
There are also plans for oral versions that could cost about $150.
In return for these lower prices, the companies get a break on certain import taxes for three years.
This is meant to help many Americans afford these medicines and improve their health.
The Trump administration has finalized agreements with Eli Lilly and Novo Nordisk to significantly lower the prices of popular weight-loss drugs like Zepbound and Wegovy.
Eligible Medicare beneficiaries will have a co-pay of $50 per month for these injectable drugs, with coverage starting mid-next year.
A new direct-to-consumer channel will offer injectable GLP-1 drugs starting at an average of $350 per month, with oral doses potentially as low as $150.
In exchange for these reduced prices and expanded access, the pharmaceutical companies will receive a three-year exemption from threatened tariffs on imported drugs.
The administration views these deals as a major success for American patients, aiming to improve health outcomes for millions and enable Medicare to cover obesity-related treatments.
- Who
- The Trump administration, Eli Lilly & Co., and Novo Nordisk
- What
- Announced deals to lower prices for popular GLP-1 weight-loss drugs like Zepbound and Wegovy for American patients.
- When
- Thursday, November 7, 2025
- Where
- The White House, Washington D.C.
- Why
- To reduce the cost of weight-loss medications for eligible Americans, particularly those on Medicare and Medicaid, in exchange for relief from threatened tariffs.
Trump Administration
Pharmaceutical Companies (Eli Lilly & Novo Nordisk)
Drug Pricing and Discounts
Trump Administration
Companies have agreed to offer popular GLP-1 weight-loss drugs like Zepbound and Wegovy at 'Most Favored Nation' rates, which are drastic discounts, with oral doses as low as around $150 for certain groups and injectables starting at an average of $350 per month via a direct-to-consumer channel. Medicare co-payment for eligible beneficiaries will be $50.
Pharmaceutical Companies (Eli Lilly & Novo Nordisk)
The companies are committing to offer specific drugs at lower rates to American patients and potentially providing lower prices to government programs and cash payers.
Incentives and Exchanges
Trump Administration
In exchange for lower prices, pharmaceutical companies will receive a three-year grace period from threatened pharmaceutical tariffs and access to beneficiaries not otherwise covered by Medicare for obesity issues. This is part of a broader effort to pressure companies into voluntarily lowering prices.
Pharmaceutical Companies (Eli Lilly & Novo Nordisk)
The companies benefit from tariff relief on pharmaceutical imports and potentially faster reviews for certain new drugs, as well as access to a larger patient pool.
Impact and Clarity
Trump Administration
The administration views the deals as a 'triumph' that will save lives, improve the health of millions, and enable Medicare to cover drugs for obesity and related comorbidities for the first time. The goal is to reduce medicine costs significantly.
Pharmaceutical Companies (Eli Lilly & Novo Nordisk)
While the deals aim for lower prices, the final cost to consumers when commercial insurance is factored in remains unclear. The agreement to lower prices is seen as a potential benefit for many people.
- Companies Involved
- Eli Lilly & Co., Novo Nordisk
- Drugs Affected
- Popular GLP-1 weight-loss drugs including Zepbound, Wegovy, Ozempic, and Mounjaro
- Oral Dose Price (potential, for certain groups)
- As low as $150
- Injectable Price (starting, direct-to-consumer)
- Average of $350 per month
- Medicare Co-payment (eligible beneficiaries)
- $50
- Medicare/Medicaid Coverage Price (starting mid-next year, with criteria)
- $245 per month
- Current US List Price for Drugs
- More than $1,000 a month
- Incentive for Companies
- Three-year grace period from threatened pharmaceutical tariffs
Sources
Eli Lilly, Novo Nordisk to lower Obesity Drug cost, strike pricing deal with Trump — 'Triumph for American patients'
Will Ozempic & Zepbound Prices Drop Under TrumpRx Deal With Eli Lilly and Novo Nordisk For GLP-1 Drugs?
Trump Unveils Deal To Expand Coverage, Lower Prices For Obesity Treatments
Media Ushered Out Of Oval Office After Man Collapses During Trump Announcement On Weight-Loss Drug Discounts
'Triumph for American patients': Trump unveils deals to slash prices of some weight-loss drugs
Trump says agreement reached with Novo Nordisk, Eli Lilly to lower GLP-1 weight loss drugs cost
Trump administration plans to lower obesity drug prices. THIS will be new rate of weight loss pills for Americans
Eli Lilly, Novo Nordisk to cut obesity drug prices after Trump administration deal
Lilly, Novo to lower obesity drug prices in Trump deal
Trump Unveils Deals To Lower Costs Of Some weight-Loss Drugs
